Tipen may be available in the countries listed below.
Ingredient matches for Tipen
Phenoxymethylpenicillin
Phenoxymethylpenicillin is reported as an ingredient of Tipen in the following countries:
- Bangladesh
International Drug Name Search
Tuesday, 17 August 2010
Etfariol
Etfariol may be available in the countries listed below.
Ingredient matches for Etfariol
Ticlopidine
Ticlopidine hydrochloride (a derivative of Ticlopidine) is reported as an ingredient of Etfariol in the following countries:
- Greece
International Drug Name Search
Tocofersolan
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
A11HA08
CAS registry number (Chemical Abstracts Service)
0030999-06-5
Chemical Formula
C33-H54-O5(C2-H4-O)n
Therapeutic Category
Vitamin E
Chemical Name
Poly(oxy-1,2-ethanediyl), alfa-[4-[[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]oxy]-1,4-dioxobutyl-omega-hydroxy-
Foreign Names
- Tocofersolanum (Latin)
- Tocofersolan (German)
- Tocofersolan (French)
- Tocofersolan (Spanish)
Generic Names
- Tocophersolan (OS: USAN)
- TPGS (IS)
Brand Names
- Vedrop
Orphan, Germany; Orphan, United Kingdom - Vitamin E Walmark
Walmark, Czech Republic
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Click for further information on drug naming conventions and International Nonproprietary Names.
Monday, 16 August 2010
Crestor
Crestor is a brand name of rosuvastatin, approved by the FDA in the following formulation(s):
CRESTOR (rosuvastatin calcium - tablet; oral)
Manufacturer: IPR
Approval date: August 12, 2003
Strength(s): 10MG, 20MG, 40MG [RLD], 5MG
Has a generic version of Crestor been approved?
No. There is currently no therapeutically equivalent version of Crestor available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Crestor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Pharmaceutical compositions
Patent 6,316,460
Issued: November 13, 2001
Inventor(s): Creekmore; Joseph R & Wiggins; Norman A.
Assignee(s): Astrazeneca AB
The invention concerns a pharmaceutical composition comprising the HMG CoA reductase inhibitor (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrim idin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient, which remains stable over a prolonged period.Patent expiration dates:
- August 4, 2020✓
- February 4, 2021✓
- August 4, 2020
Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
Patent 6,858,618
Issued: February 22, 2005
Inventor(s): Raza; Ali & Hutchinson; Howard Gerard
Assignee(s): AstraZeneca AB
The invention provides a method for the treatment of heterozygous familial hypercholesterolemia by administering the compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof.Patent expiration dates:
- December 17, 2021✓
- June 17, 2022✓
- December 17, 2021
Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Patent 7,030,152
Issued: April 18, 2006
Inventor(s): Ridker; Paul & Hennekens; Charles H.
Assignee(s): The Brigham and Women's Hospital, Inc.
The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.Patent expiration dates:
- April 2, 2018✓
- October 2, 2018✓
- April 2, 2018
Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Patent 7,964,614
Issued: June 21, 2011
Inventor(s): Ridker; Paul & Hennekens; Charles H.
Assignee(s): The Brigham and Women's Hospital, Inc.
The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.Patent expiration dates:
- April 2, 2018✓
- October 2, 2018✓
- April 2, 2018
Pyrimidine derivatives
Patent RE37314
Issued: August 7, 2001
Inventor(s): Hirai; Kentaro & Ishiba; Teruyuki & Koike; Haruo & Watanabe; Masamichi
Assignee(s): Shionogi Seiyaku Kabushiki Kaisha
The compounds of the present invention inhibit the HMG-CoA reductase, and subsequently suppress the biosynthesis of cholesterol. And they are useful in the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis.Patent expiration dates:
- January 8, 2016✓
- July 8, 2016✓
- January 8, 2016
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- November 8, 2010 - ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
- May 8, 2011 - PEDIATRIC EXCLUSIVITY
- November 6, 2011 - TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
- May 6, 2012 - PEDIATRIC EXCLUSIVITY
- October 16, 2012 - TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
- February 8, 2013 - PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
- April 16, 2013 - PEDIATRIC EXCLUSIVITY
See also...
- Crestor Consumer Information (Drugs.com)
- Crestor Consumer Information (Wolters Kluwer)
- Crestor Consumer Information (Cerner Multum)
- Crestor Advanced Consumer Information (Micromedex)
- Crestor AHFS DI Monographs (ASHP)
- Rosuvastatin Consumer Information (Wolters Kluwer)
- Rosuvastatin Consumer Information (Cerner Multum)
- Rosuvastatin Advanced Consumer Information (Micromedex)
- Rosuvastatin Calcium AHFS DI Monographs (ASHP)
Friday, 6 August 2010
Anargil
Anargil may be available in the countries listed below.
Ingredient matches for Anargil
Danazol
Danazol is reported as an ingredient of Anargil in the following countries:
- Bangladesh
- Slovakia
- Thailand
- Vietnam
International Drug Name Search
Sunday, 25 July 2010
Avodart
Avodart is a brand name of dutasteride, approved by the FDA in the following formulation(s):
AVODART (dutasteride - capsule; oral)
Manufacturer: GLAXOSMITHKLINE
Approval date: November 20, 2001
Strength(s): 0.5MG [RLD][AB]
Has a generic version of Avodart been approved?
A generic version of Avodart has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Avodart and have been approved by the FDA:
dutasteride capsule; oral
Manufacturer: BARR
Approval date: December 21, 2010
Strength(s): 0.5MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avodart. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Androstenone derivative
Patent 5,565,467
Issued: October 15, 1996
Inventor(s): Batchelor; Kenneth W. & Frye; Stephen V. & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
Assignee(s): Glaxo Wellcome Inc.
The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.Patent expiration dates:
- November 20, 2015✓✓
- November 20, 2015
Androstenone derivative
Patent 5,846,976
Issued: December 8, 1998
Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
Assignee(s): Glaxo Wellcome Inc.
The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.Patent expiration dates:
- September 17, 2013✓
- September 17, 2013
Androstenones
Patent 5,998,427
Issued: December 7, 1999
Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon
Assignee(s): Glaxo Wellcome Inc.
The present invention relates to compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; R.sup.3 is (B) wherein X, R.sup.6, R.sup.7 and R.sup.8 are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases. ##STR1##Patent expiration dates:
- September 17, 2013✓✓✓
- September 17, 2013
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- June 19, 2011 - USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
See also...
- Avodart Consumer Information (Drugs.com)
- Avodart Consumer Information (Wolters Kluwer)
- Avodart Consumer Information (Cerner Multum)
- Avodart Advanced Consumer Information (Micromedex)
- Avodart AHFS DI Monographs (ASHP)
- Dutasteride Consumer Information (Wolters Kluwer)
- Dutasteride Consumer Information (Cerner Multum)
- Dutasteride Advanced Consumer Information (Micromedex)
- Dutasteride AHFS DI Monographs (ASHP)
Friday, 23 July 2010
Vastcillin
Vastcillin may be available in the countries listed below.
Ingredient matches for Vastcillin
Ciclacillin
Ciclacillin is reported as an ingredient of Vastcillin in the following countries:
- Japan
International Drug Name Search
Subscribe to:
Posts (Atom)